EDGAR·FLOW

Caribou Biosciences, Inc. — Form 8-K

Filed November 5, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 92/100
What the filing says
On October 6, 2026, Caribou's Board approved a restructuring and announced exploration of strategic alternatives (merger, acquisition, or dissolution) after deciding to discontinue clinical trials for its two lead programs—vispa-cel and CB-011—and implement substantial workforce reductions. The decision follows challenging financing conditions for allogeneic CAR-T therapies. Q3 2026 showed cash/equivalents of $94.8M (down 34% from $142.8M at year-end 2025) and net loss of $26.6M ($0.25/share), with licensing revenue declining to $1.6M from $2.2M year-over-year.
Why this rating

Discontinuation of all clinical development and existential strategic review represents near-total business pivot for $112.5M biotech. Cash burn and asset depletion material to company size.

Tradability signal
NO TRADE

No trade: price $0.42 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$0.41 ▲ 0.44%
at our read · unknown
$0.41
+10 min · unknown
$0.41 ▲ 0.46%
+30 min · unknown
$0.42 ▲ 1.41%
+1 hr · unknown
$0.42 ▲ 1.46%
+4 hrs · unknown
$0.42 ▲ 2.36%

The stock had already moved -0.44% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ CRBU · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.